XVIVO PERFUSION AB

XVIVO PERFUSION AB Share · SE0004840718 · A1J5GZ (XSTO) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of XVIVO PERFUSION AB
No Price
Closing Price XSTO 30.04.2026: 274,40 SEK
30.04.2026 20:00
Current Prices from XVIVO PERFUSION AB
ExchangeTickerCurrencyLast TradePriceDaily Change
OTC: UTC
UTC
XVIPF
USD
30.04.2026 20:00
22,81 USD
0,00 USD
XDUS: Düsseldorf
Düsseldorf
XPABNA18.DUSB
EUR
30.04.2026 17:32
25,02 EUR
-1,04 EUR
-3,99 %
XSTO: NASDAQ STOCKHOLM AB
NASDAQ STOCKHOLM AB
XVIVO.ST
SEK
30.04.2026 10:59
274,40 SEK
-
XLON: London
London
0RKL.L
SEK
30.04.2026 10:47
274,00 SEK
-
XDQU: Quotrix
Quotrix
XPABNA18.DUSD
EUR
30.04.2026 05:27
25,30 EUR
-
Share Float & Liquidity
Free Float 79,79 %
Shares Float 25,13 M
Shares Outstanding 31,5 M
Invested Funds

The following funds have invested in XVIVO PERFUSION AB:

Fund
iShares OMX Stockholm Capped UCITS ETF
Vol. in million
9.042,72
Percentage (%)
0,13 %
Company Profile for XVIVO PERFUSION AB Share
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

Company Data

Name XVIVO PERFUSION AB
Company Xvivo Perfusion AB (publ)
Website https://www.xvivoperfusion.com
Primary Exchange XSTO NASDAQ STOCKHOLM AB
WKN A1J5GZ
ISIN SE0004840718
Asset Class Share
Sector Healthcare
Industry Medical - Devices
CEO Christoffer Rosenblad
Market Capitalization 9 Mrd.
Country Sweden
Currency SEK
Employees 0,2 T
Address MAessans gata 10, 412 51 Gothenburg
IPO Date 2012-10-08
Dividends from 'XVIVO PERFUSION AB'
Ex-Date Dividend per Share
15.03.2022 0,29 SEK

Ticker Symbols

Name Symbol
NASDAQ STOCKHOLM AB XVIVO.ST
Over The Counter XVIPF
Düsseldorf XPABNA18.DUSB
Frankfurt 3XV.F
London 0RKL.L
Quotrix XPABNA18.DUSD
More Shares
Investors who hold XVIVO PERFUSION AB also have the following shares in their portfolio:
LB.HESS.THR. IHS 19/31
LB.HESS.THR. IHS 19/31 Bond
Valkyrie Bitcoin Miners ETF
Valkyrie Bitcoin Miners ETF ETF